These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 18937578)

  • 41. [Use of antiretroviral agents in cirrhotic patients infected by HIV].
    Salmon-Céron D
    Med Mal Infect; 2004 Nov; 34 Spec No 2():14-9. PubMed ID: 15801534
    [No Abstract]   [Full Text] [Related]  

  • 42. Three cases of autoimmune hepatitis in HIV-infected patients.
    Puius YA; Dove LM; Brust DG; Shah DP; Lefkowitch JH
    J Clin Gastroenterol; 2008 Apr; 42(4):425-9. PubMed ID: 18277893
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of antiretroviral therapy on asymptomatic malaria parasitaemia in HIV-1 infected children.
    Adetifa IM; Akinsulie AO; Temiye EO; Iroha EO; Ezeaka VC; Mafe AG; Grange AO
    Niger Postgrad Med J; 2008 Sep; 15(3):141-5. PubMed ID: 18923585
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combining evidence for access to and benefits from antiretroviral treatment to inform planning.
    ; Marlink R; Forsythe S; Bertozzi SM; Muirhead D; Holmes M; Sturchio J
    AIDS; 2008 Jul; 22 Suppl 1():S121-2. PubMed ID: 18664943
    [No Abstract]   [Full Text] [Related]  

  • 45. Reversible posterior leukoencephalopathy syndrome in 2 HIV-infected patients receiving antiretroviral therapy.
    Ridolfo AL; Resta F; Milazzo L; Caramma I; Matacena G; Antinori S; Galli M
    Clin Infect Dis; 2008 Jan; 46(2):e19-22. PubMed ID: 18171242
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antiretroviral therapy adherence in children: outcomes from Africa.
    Reddi A; Leeper SC
    AIDS; 2008 Apr; 22(7):906-7. PubMed ID: 18427213
    [No Abstract]   [Full Text] [Related]  

  • 47. [HIV antiretroviral agents: new threats to accessibility in developing countries].
    Nau JY
    Rev Med Suisse; 2005 Dec; 1(45):2956. PubMed ID: 16425957
    [No Abstract]   [Full Text] [Related]  

  • 48. HIV and the liver.
    Rockstroh J
    J HIV Ther; 2009 Mar; 14(1):2-3. PubMed ID: 19731557
    [No Abstract]   [Full Text] [Related]  

  • 49. Impact of lipoatrophy on patient-reported outcomes in antiretroviral-experienced patients.
    Doward LC; Dietz B; Wilburn J; McKenna SP; Bhor M; Rajagopalan R
    AIDS Read; 2008 May; 18(5):242-6, 252-6, 262-4. PubMed ID: 18589480
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Liver disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation.
    Vogel M; Rockstroh JK
    Curr Opin HIV AIDS; 2009 May; 4(3):171-5. PubMed ID: 19532046
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cutaneous drug reactions associated with newer antiretroviral agents.
    Martins CR
    J Drugs Dermatol; 2006; 5(10):976-82. PubMed ID: 17373147
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Follow up of HIV-infected patients on antiretroviral treatment].
    Chirouze C; Hoen B
    Rev Prat; 2006 May; 56(9):966-75. PubMed ID: 16775977
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Strategies for managing coinfection with hepatitis B virus and HIV.
    Sherman M
    Cleve Clin J Med; 2009 May; 76 Suppl 3():S30-3. PubMed ID: 19465707
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adverse interactions with antiretroviral agents: focus on recreational and addiction drugs.
    Vassilev ZP; Marcus SM
    AIDS Read; 2004 Feb; 14(2):96. PubMed ID: 15083804
    [No Abstract]   [Full Text] [Related]  

  • 55. Bone mineral abnormalities in persons with HIV infection: signal or noise?
    Singh K; Moyle GJ
    AIDS Read; 2006 Aug; 16(8):407-10, 413-8. PubMed ID: 16933375
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The obligation to provide antiretroviral treatment in HIV prevention trials.
    Lo B; Padian N; Barnes M
    AIDS; 2007 Jun; 21(10):1229-31. PubMed ID: 17545698
    [TBL] [Abstract][Full Text] [Related]  

  • 57. When to switch for antiretroviral treatment failure in resource-limited settings?
    Vekemans M; John L; Colebunders R
    AIDS; 2007 May; 21(9):1205-6. PubMed ID: 17502731
    [No Abstract]   [Full Text] [Related]  

  • 58. Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy.
    Crane M; Oliver B; Matthews G; Avihingsanon A; Ubolyam S; Markovska V; Chang JJ; Dore GJ; Price P; Visvanathan K; French M; Ruxrungtham K; Lewin SR
    J Infect Dis; 2009 Apr; 199(7):974-81. PubMed ID: 19231993
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.
    Murillas J; Rimola A; Laguno M; de Lazzari E; Rascón J; Agüero F; Blanco JL; Moitinho E; Moreno A; Miró JM;
    Liver Transpl; 2009 Sep; 15(9):1133-41. PubMed ID: 19718643
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New 2011 updated DHHS antiretroviral treatment guidelines and chronic hepatitis B.
    Soriano V; Vispo E; Barreiro P
    AIDS; 2011 Apr; 25(7):1013-4. PubMed ID: 21487255
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.